How long does the entire development process take?

The timeline varies based on the vaccine platform. Generally, our streamlined workflow for peptide or mRNA vaccines allows for candidate delivery within 4-8 weeks from sample receipt.

Do you offer GMP manufacturing for clinical trials?

Currently, our primary focus is on research-grade and preclinical GLP-grade production. However, we can support technology transfer and process development to facilitate your transition to GMP manufacturing.

Personalized Neoantigen Cancer Vaccine Development Solution

Personalized neoantigen cancer vaccines represent a breakthrough in precision immunotherapy. Unlike shared tumor-associated antigens (TAAs), neoantigens are derived from tumor-specific mutations unique to each patient, making them highly immunogenic and less likely to cause central tolerance or off-target toxicity. These vaccines work by training the patient's immune system to recognize and attack cells displaying these specific mutations.

At Creative Biolabs, we provide a one-stop "Personalized Neoantigen Cancer Vaccine Development Solution" tailored to the specific needs of global researchers and pharmaceutical developers. Leveraging decades of experience in vaccine engineering, we offer an integrated pipeline that spans from tumor sequencing and AI-driven neoepitope prediction to vaccine design, formulation, and preclinical validation.

Get a Quote

Key Challenges in Neoantigen Research

Despite the promise of neoantigen vaccines, researchers face several critical hurdles:

▶ Accurate Prediction: Identifying true immunogenic neoantigens from thousands of somatic mutations remains a "needle in a haystack" problem due to the complexity of HLA binding and T-cell recognition.
▶ Delivery Efficiency: Developing stable and effective delivery systems (like LNPs) that ensure the vaccine reaches antigen-presenting cells (APCs) is technically demanding.
▶ Turnaround Time: The personalized nature of these therapies requires rapid manufacturing processes to meet the therapeutic window for cancer patients.
▶ Tumor Microenvironment (TME): Overcoming the immunosuppressive TME to ensure activated T cells can effectively infiltrate and kill tumor cells.

Consult Our Experts

Our Solutions

Creative Biolabs addresses these challenges through a synergistic combination of advanced biotechnology and computational power. We provide:

End-to-End Development

A seamless workflow from patient sample sequencing to the final vaccine formulation.

Multiple Vaccine Modalities

Flexibility to choose between mRNA, peptide, dendritic cell, or viral vector-based platforms based on project requirements.

Proprietary Algorithms

Advanced AI platforms that significantly improve the accuracy of neoantigen prediction and immunogenicity scoring.

Optimized Delivery Systems

Cutting-edge lipid nanoparticles (LNP) and biomaterial scaffolds to enhance antigen stability and uptake.

Featured Services

We offer a diverse portfolio of specialized platforms to support every aspect of neoantigen vaccine development:

Personalized Neoepitope mRNA Cancer Vaccine Platform

We utilize advanced in vitro transcription (IVT) technology and proprietary cap/tail modifications to generate high-stability mRNA vaccines. Our service includes LNP encapsulation to ensure efficient delivery and potent immune activation.

Learn More →

Modular NeoVax Platform for Cancer Vaccine

Our modular approach allows for the rapid assembly of vaccine components. This "plug-and-play" system significantly reduces development time, allowing for quick adaptation to identified neoantigens.

Learn More →

Synthetic Long Peptides (SLPs) Based Neoantigen Cancer Vaccines

We specialize in the synthesis of high-purity long peptides. SLPs are processed more efficiently by dendritic cells compared to short peptides, leading to a robust CD4+ and CD8+ T cell response.

Learn More →

Dendritic Cell (DCs) Based Neoantigen Cancer Vaccines

We offer ex vivo generation and loading of autologous dendritic cells with specific neoantigens. This cellular vaccine strategy ensures precise antigen presentation and strong T-cell priming.

Learn More →

Biomaterial-assisted Neoantigen Cancer Vaccines

Creative Biolabs develops novel biomaterial scaffolds and implants that mimic the immune microenvironment, enabling sustained antigen release and recruiting immune cells to the injection site for enhanced efficacy.

Learn More →

AI-aided Analysis Platform for Prediction

Our bioinformatics team employs deep learning algorithms to analyze NGS data, predicting HLA binding affinity, proteasomal cleavage, and T-cell receptor recognition with high predictive positive values (PPV).

Learn More →

High-efficient In Vitro Evaluation Platform

Before animal studies, we validate candidate neoantigens using high-throughput assays, including ELISpot, intracellular cytokine staining (ICS), and MHC multimer binding assays to confirm immunogenicity.

Learn More →

Adoptive Neoantigen-activated T Cell Transfer Therapy

We provide services to isolate and expand Tumor-Infiltrating Lymphocytes (TILs) or peripheral T cells that are reactive to specific neoantigens for adoptive cell therapy applications.

Learn More →

NeoTCR-T Platform

We engineer T cells with T-cell receptors (TCRs) that specifically recognize identified neoantigens, creating "living drugs" that can target and eliminate tumor cells with high specificity.

Learn More →

Service Workflow

Our streamlined process ensures transparency and quality at every step:

Step 1: Sample Collection & Sequencing

Service: DNA/RNA extraction from tumor and normal tissue, followed by WES/RNA-Seq.

Deliverable: Raw sequencing data and quality control reports.

Step 2: Neoantigen Prediction & Selection

Service: Bioinformatics analysis to identify somatic mutations and predict high-affinity neoepitopes.

Deliverable: Ranked list of candidate neoantigens with immunogenicity scores.

Step 3: Vaccine Design & Manufacturing

Service: Synthesis of peptides, mRNA, or viral vectors; formulation (e.g., LNP).

Deliverable: Formulated vaccine candidates ready for testing.

Step 4: In Vitro Validation

Service: DC loading and T-cell co-culture assays.

Deliverable: Data on T-cell activation and cytokine release.

Step 5: Preclinical Efficacy Evaluation (Optional)

Service: Tumor challenge studies in humanized mouse models.

Deliverable: Comprehensive final report including tumor growth curves and survival analysis.

We offer flexibility, allowing clients to initiate the collaborative process at any of these phases based on their current development needs.

Start Your Project

Technology Platforms

Our solutions are underpinned by state-of-the-art technologies:

Whole Exome Sequencing (WES) and RNA-Seq for mutation detection.

High-depth sequencing of tumor and normal tissue
Accurate identification of somatic mutations
Transcriptome analysis for expression validation

Cloud-based pipelines for mutation calling and epitope selection.

Advanced AI algorithms for neoepitope prediction
Immunogenicity scoring and ranking
HLA binding affinity analysis

Molecular docking simulations for pMHC-TCR interactions.

3D modeling of peptide-MHC complexes
Prediction of TCR recognition potential
Structural validation of candidate antigens

For precise LNP formulation and encapsulation.

High-efficiency mRNA encapsulation
Controlled particle size and distribution
Scalable manufacturing process

Next-Generation Sequencing (NGS)

Bioinformatics & AI

Structural Biology

Microfluidics

Inquire About Our Technology

Why Choose Creative Biolabs

Extensive Expertise

Over 15 years of experience in vaccine development and immunotherapy.

High Customization

Solutions tailored to specific tumor types and research goals.

Reliable Quality

Adherence to strict quality control standards ensuring reproducibility.

Global Support

A dedicated team of PhD-level scientists available for technical consultation 24/7.

Request a Free Consultation

Backgrounds & Applications

Research into personalized neoantigen vaccines is reshaping oncology. Unlike traditional chemotherapy, these vaccines target the unique genetic fingerprint of a patient’s tumor.

Major Applications Include:

✓ Solid Tumors: Melanoma, Non-Small Cell Lung Cancer (NSCLC), and Glioblastoma, where high mutational burdens provide abundant neoantigen targets.
✓ Combination Therapies: Synergistic use with Immune Checkpoint Inhibitors (PD-1/PD-L1 blockade) to overcome resistance mechanisms.
✓ Metastatic Cancers: Targeting systemic disease by inducing a systemic memory T-cell response.

Discuss Application Strategy

Frequently Asked Questions

Q: What is the main difference between TAA and Neoantigen vaccines?

A: TAAs (Tumor-Associated Antigens) are found on both normal and cancer cells, which can lead to autoimmune side effects. Neoantigens are formed by tumor-specific mutations and are not present in healthy tissues, offering higher specificity and safety.

Q: What does Creative Biolabs’ Personalized Neoantigen Vaccine Development service cover?

A: Our comprehensive solution covers the entire pre-clinical workflow, starting from tumor profiling to vaccine candidate validation. The pipeline includes: 1. Tumor/Normal Whole Exome Sequencing (WES) and RNA Sequencing. 2. Bioinformatics analysis for neoantigen identification and prioritization. 3. Vaccine design and synthesis (Peptides, mRNA, DNA, etc.). 4. Formulation with delivery systems or adjuvants. 5. In vitro immunogenicity testing. 6. In vivo antitumor efficacy evaluation in animal models.

Q: Can you handle samples with low mutational burden?

A: Yes. Our sensitive sequencing and advanced prediction algorithms are designed to identify rare but potent neoepitopes even in "cold" tumors or cancers with lower mutational loads.

Q: How do you select the best neoantigen candidates?

A: We utilize a proprietary bioinformatics pipeline that integrates multiple factors to predict immunogenicity. This includes:

MHC Binding Affinity: Predicting how well the peptide binds to specific MHC Class I and II alleles.

Expression Levels: verifying the mutation is expressed using RNA-seq data.

Clonality: Prioritizing clonal mutations found in the majority of tumor cells.

Dissimilarity to Self: Ensuring the neoantigen is distinct enough from the wild-type sequence to trigger a T-cell response without autoimmunity.

Q: What types of delivery systems do you provide for RNA vaccines?

A: We specialize in Lipid Nanoparticles (LNPs) which are the gold standard for mRNA delivery. We also offer liposomes and polymeric nanoparticles, customizable to target specific tissues or dendritic cells.

Ask Our Experts

Related Resources